Glomerulonephritis minimal lesion – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:27 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Glomerulonephritis minimal lesion – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Frexalimab, SAR442970, and Rilzabrutinib for Patients Aged 16-75 with Focal Segmental Glomerulosclerosis or Minimal Change Disease https://clinicaltrials.eu/trial/study-on-frexalimab-sar442970-and-rilzabrutinib-for-patients-aged-16-75-with-focal-segmental-glomerulosclerosis-or-minimal-change-disease/ Wed, 29 Apr 2026 15:02:07 +0000 https://clinicaltrials.eu/trial/study-on-frexalimab-sar442970-and-rilzabrutinib-for-patients-aged-16-75-with-focal-segmental-glomerulosclerosis-or-minimal-change-disease/ This clinical trial is focused on studying two kidney diseases: Primary Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD). These are conditions that affect the kidney’s ability to filter waste and excess fluids from the blood. The study will evaluate the effectiveness and safety of three treatments: Frexalimab, SAR442970, and Rilzabrutinib. Frexalimab and SAR442970 are given as injections, while Rilzabrutinib is taken as a tablet. The study also includes a placebo group for comparison.

The purpose of the study is to see how well these treatments can reduce protein levels in the urine, which is a sign of kidney damage. Participants in the study will receive one of the treatments or a placebo and will be monitored over a period of time to assess changes in their condition. The study will also track any side effects or adverse reactions to the treatments.

Participants will be randomly assigned to receive either Frexalimab, SAR442970, Rilzabrutinib, or a placebo. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. The trial aims to provide valuable information on the potential benefits and risks of these treatments for people with FSGS or MCD.

]]> Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-sparsentan-for-children-with-proteinuric-kidney-diseases/ Wed, 29 Apr 2026 14:28:04 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-sparsentan-for-children-with-proteinuric-kidney-diseases/ This clinical trial is focused on studying certain kidney diseases known as proteinuric glomerular diseases. These include conditions like Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), Immunoglobulin A Vasculitis (IgAV), and Alport Syndrome (AS). The treatment being tested is a medication called Sparsentan, which is given as an oral suspension. The purpose of the study is to evaluate the safety and effectiveness of Sparsentan in children with these kidney diseases.

Participants in the study will receive Sparsentan once daily for a period of 108 weeks. During this time, researchers will monitor the safety of the medication and observe any changes in the levels of protein in the urine, which is a key indicator of kidney health. The study aims to understand how well Sparsentan works in reducing protein levels in the urine and how the body processes the medication over time.

The study will also look at how many participants experience a complete or partial remission of their kidney disease symptoms, such as a significant reduction in protein levels in the urine. Additionally, researchers will track any side effects that occur during the study, including any that might lead to stopping the treatment. This information will help determine the overall safety and potential benefits of Sparsentan for treating these specific kidney diseases in children.

]]>